Paxman Neuropathy Device Advances to FDA Substantive Review

• Paxman's neuropathy device De Novo application advanced to FDA substantive review following completion of its acceptance review.
• The cryocompression device aims to prevent chemotherapy-induced peripheral neuropathy; the FDA will assess clinical, technical and supporting evidence.
• The 150-review-day target period began October 26, 2026, with 134 review days remaining.
• Requests for additional information can pause the review clock while responses are prepared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paxman AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.